Epoetin delta
Also known as: DeltaEPO, Dynepo, epoetin delta, PD-001, r-HuEPO delta
Source Epoetin delta at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Epoetin delta is a recombinant human erythropoietin produced in human fibrosarcoma (HT‑1080) cells, engineered by homologous recombination to express the native EPO gene with human‑type glycosylation. It was intended as a short‑acting erythropoiesis‑stimulating agent for anemia of chronic kidney disease. Although it achieved regulatory approval in some jurisdictions, the product was later withdrawn for commercial reasons and is not presently marketed.
Mechanism of Action
Epoetin delta binds the erythropoietin receptor (EPO‑R) on erythroid progenitor cells in the bone marrow. Receptor activation triggers the JAK2‑STAT5 signaling cascade, promoting proliferation, survival and differentiation of these cells, ultimately increasing red‑blood‑cell production. Its human‑cell derived glycosylation pattern is intended to mimic native EPO, potentially reducing immunogenicity compared with CHO‑derived ESAs.
What the Research Shows
The literature on epoetin delta is sparse. Early reviews describe its production in human cells and note that it was recently approved for chronic kidney disease‑related anemia, but few clinical data are available. A 2017 Cochrane review identified two randomized trials that compared epoetin delta with epoetin alpha; however, results were not reported because the sponsor withdrew the product for commercial reasons. No efficacy or safety outcomes have been published. Doping‑control studies document the detection of delta in athletes, highlighting its distinct isoform pattern. Overall, evidence is limited to pre‑clinical characterization and unpublished early‑phase trials.
Reported Benefits
When administered, epoetin delta is intended to raise hemoglobin levels in patients with CKD‑related anemia, reducing reliance on blood transfusions and improving fatigue. Its human‑cell glycosylation was expected to provide potency comparable to other short‑acting ESAs, potentially allowing similar dosing schedules. No published trials confirm these benefits.
Limitations of the Evidence
Published data on efficacy and safety are lacking; the only identified clinical trials did not report outcomes before the product’s commercial withdrawal. Consequently, the magnitude of hemoglobin response, optimal dosing frequency, and comparative advantage over existing ESAs remain unknown. The withdrawal also means the drug is unavailable for clinical use, limiting real‑world experience.
Safety Considerations
General risks associated with erythropoiesis‑stimulating agents—such as hypertension, thromboembolic events, and pure red‑cell aplasia—apply, but specific safety data for epoetin delta are absent from the literature. Anti‑EPO antibody formation has been reported with some ESAs, particularly after subcutaneous use, and could theoretically occur with delta. Doping‑control reports describe its detection but do not detail adverse clinical effects. Caution is advised pending robust safety evaluations.
How It Is Administered
Epoetin delta is formulated as an injectable protein and can be administered intravenously or subcutaneously. Dosing regimens were expected to mirror those of other short‑acting ESAs, with weekly or bi‑weekly injections, but the product is no longer marketed, so no current prescribing information exists.
Routes of Administration
Goals & Uses
- Anemia in cancer chemotherapy patientsOncology/HematologyLow
- Anemia of chronic kidney diseaseHematologyHigh
- Reduction of allogeneic blood transfusionsPerioperative MedicineModerate
- Treatment of anemia in chronic renal failureHematology/NephrologyHigh
- Chemotherapy‑induced anemiaOncologyHigh
Contraindications
- Known hypersensitivity to epoetin productsImmunologicHigh
- Hypersensitivity to epoetin delta or excipientsImmunologicalHigh
- Uncontrolled hypertensionCardiovascularHigh
- Hemoglobin ≥12 g/dL in cancer patientsOncologyModerate
- Pure red cell aplasia (PRCA) due to prior ESA therapyImmunologicalHigh
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- HypertensionCardiovascularCommonHigh blood pressure
- Injection site reactionsLocalCommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Thromboembolic eventsCardiovascularUncommon
- Pure red cell aplasia (PRCA)Immunological / HematologicalRare
- Thrombotic/thromboembolic eventsCardiovascular / HematologicalUncommon
Drug Interactions
- Antihypertensive agentsModerate
- CyclosporineModerate
- Iron supplementsLow
- Iron supplementationLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Cancer patients receiving curative-intent chemotherapyOncologyRelative
- Pediatric patientsAgeRelative
- Patients with cardiovascular diseaseComorbidityRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: Anemia due to chronic kidney disease, Chemotherapy‑induced anemia, HIV‑related anemiaApproved as a biosimilar to epoetin alfa.
- United StatesInvestigationalNot FDA‑approved; under clinical investigation.
- United KingdomWithdrawnApproved: Anemia in chronic renal failureWas available as part of EU approval; no longer marketed following 2008 withdrawal.
Approved in the European Union as a biosimilar to epoetin alfa; not approved by the US FDA as of 2024.
Evidence & Sources
- Journal ArticleModerateJelkmann W2009-01-01T00:00:00.000000Z
- Journal ArticleModerateDeicher R, Hörl WH2004-01-01T00:00:00.000000Z
- Journal ArticleModerateJelkmann W2007-01-01T00:00:00.000000Z
- Journal ArticleHighHahn D, et al.2017-01-01T00:00:00.000000Z
- Journal ArticleModerateGmeiner G, et al.2010-01-01T00:00:00.000000Z
- Journal ArticleModerateGoldsmith D2010-01-01T00:00:00.000000Z
Frequently Asked Questions
What distinguishes epoetin delta from other ESAs?
Epoetin delta is produced in human fibrosarcoma cells, giving it a human‑type glycosylation pattern that lacks the non‑human N‑glycolylneuraminic acid found in CHO‑derived ESAs. This manufacturing difference was intended to reduce immunogenicity, though clinical data confirming an advantage are not available.
Why is epoetin delta no longer available?
Although it received regulatory approval for treating anemia in chronic kidney disease, the manufacturer withdrew the product for commercial reasons. Consequently, it was never widely marketed and is not currently supplied for clinical use.
Has epoetin delta been shown to improve hemoglobin levels?
No published randomized trials have reported hemoglobin outcomes for epoetin delta. Two trials comparing it with epoetin alpha were identified, but their results were not released before the drug’s withdrawal, leaving its efficacy unproven.
Are there special safety concerns with epoetin delta?
Safety concerns are inferred from the class of ESAs and include hypertension, clotting risk, and rare pure red‑cell aplasia. Specific adverse‑event data for epoetin delta are lacking, so the overall safety profile remains uncertain.
What is Epoetin delta?
Epoetin delta is a recombinant human erythropoietin produced in human fibrosarcoma (HT‑1080) cells, engineered by homologous recombination to express the native EPO gene with human‑type glycosylation. It was intended as a short‑acting erythropoiesis‑stimulating agent for anemia of chronic kidney disease. Although it achieved regulatory approval in some jurisdictions, the product was later withdrawn for commercial reasons and is not presently marketed.
What is Epoetin delta used for?
Epoetin delta is educationally associated with: Anemia in cancer chemotherapy patients, Anemia of chronic kidney disease, Reduction of allogeneic blood transfusions, Treatment of anemia in chronic renal failure, Chemotherapy‑induced anemia. Educational only — not medical advice.
How is Epoetin delta administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Epoetin delta?
Reported adverse effects include: Flu-like symptoms, Hypertension, Injection site reactions, Headache, Thromboembolic events, Pure red cell aplasia (PRCA), Thrombotic/thromboembolic events. This list is not exhaustive — consult a qualified clinician.
Who should avoid Epoetin delta?
Recorded contraindications: Known hypersensitivity to epoetin products, Hypersensitivity to epoetin delta or excipients, Uncontrolled hypertension, Hemoglobin ≥12 g/dL in cancer patients, Pure red cell aplasia (PRCA) due to prior ESA therapy. Consult a qualified clinician before use.